Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.

Markets

Performance of psychedelic public companies this past week.

Company News

Optimi Health ($OPTI | $OPTHF) completed the largest legal natural psilocybin harvest in Canadian history. Optimi Health is licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances. Press Release          

MindMed ($MNMD | $MMED) provided positive results from their Phase II LSD study. The study found that acute administration of LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms for up to 16 weeks. Press Release          

‍Algernon Pharmaceuticals ($AGN | $AGNPF) will be the Headline Sponsor for Wonderland, the world’s largest conference in the psychedelic medicine sector, which will be held in Miami from November 3-5th. Press Release          

PharmaTher Holdings ($PHRM | $PHRRF) completed an IND-enabling pharmacokinetic and tolerability study of KETARX Ketamine Patch. The ketamine patch demonstrated extended delivery of ketamine over 40 hours. Press Release          

Nirvana Life Sciences ($NIRV) announced the development of a novel method of producing MDMA that reduces manufacturing time by two thirds. Nirvana has filed an Application with the US Patent Office for this new method. Press Release          

‍BetterLife Pharma ($BETR | $BETRF) announced that they are working with their collaborators on a key research publication on BETR-001, their proprietary 2-bromo-LSD, and plans to submit it to a peer-reviewed journal by end of September. Press Release          

Media

The Washington Post: Psilocybin As A Mental Health Therapy? Some Things To Know.

VICE: San Francisco Just Decriminalized Psychedelics

The Times: Psychedelics For Depression: Can This Trial Lead To A New NHS Therapy?

Forbes: As Use Of The World’s Most Potent Psychedelic Skyrockets, New Site F.I.V.E. Fills An Education Void

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.